Taken together, our findings provide strong evidence for scIgGs as a mechanism of cancer evasion of NK cell killing and shed lights on a potential new immune-therapeutic strategy through activation of Fc/FcγR interactions for enhancing anticancer immunity. This evidence concerns the gene FCGR2A and cancer.